"number of patients for CORAL, and expected (estimated) time-frame to completion and read out once commenced?"
To my knowledge, to date, this is all undermined. I'm sure this information will follow the Type C meeting with FDA, to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients, scheduled for this month.
Koo